Hanlin Gao Sells 563 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 563 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $12,853.29. Following the transaction, the insider now owns 924,560 shares in the company, valued at approximately $21,107,704.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Fulgent Genetics Stock Down 2.4 %

Shares of Fulgent Genetics stock opened at $22.56 on Friday. Fulgent Genetics, Inc. has a twelve month low of $18.91 and a twelve month high of $33.97. The company has a market cap of $675.09 million, a price-to-earnings ratio of -4.05 and a beta of 1.37. The company’s 50 day moving average is $22.32 and its 200 day moving average is $21.97.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, August 2nd. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. The company had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. Fulgent Genetics’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.33) earnings per share. Sell-side analysts expect that Fulgent Genetics, Inc. will post -2.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Fulgent Genetics

A number of institutional investors and hedge funds have recently made changes to their positions in FLGT. Asset Dedication LLC purchased a new stake in Fulgent Genetics during the second quarter valued at approximately $33,000. nVerses Capital LLC purchased a new position in shares of Fulgent Genetics during the 2nd quarter worth $43,000. Signaturefd LLC grew its position in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after acquiring an additional 1,132 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Fulgent Genetics during the 2nd quarter valued at $63,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Fulgent Genetics in the 1st quarter worth $178,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.